← Leaderboards
David Cobrinik
Columbia University Health Sciences
$7,124,771
Attributed
$7,351,646
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $778.7K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,351,646 · 4
By mechanism
R01$6,897,896 · 3
R21$453,750 · 1
Top collaborators
- Mark Stephen Borchert2 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Thomas L. Nickolas$5,747,594
- Adi Cohen$3,447,742
- Shonni J Silverberg$7,628,013
- Michelle P Warren$1,263,639
- Sachin Jambawalikar$1,654,511
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsCell TypeSignal TransductionIn VitroIn VivoMediatingProteinsTissuesConeRetinaSignal PathwayRetinal ConeMalignant NeoplasmsProliferatingRb1 GeneTumorigenesisRetinoblastomaOncogenicResponseMutationCell CycleGene ExpressionTumorPrecursor Cell
Grant awards (21)
Production and progression of premalignant retinoblastoma lesions.$560,197
R01 · FY2025 · CA · contact PI
Production and progression of premalignant retinoblastoma lesions.$560,196
R01 · FY2024 · CA · contact PI
Successive responses to oncogenic aberrations in retinoblastoma genesis.$322,416
R01 · FY2023 · CA · contact PI
Successive responses to oncogenic aberrations in retinoblastoma genesis.$322,416
R01 · FY2022 · CA · contact PI
Successive responses to oncogenic aberrations in retinoblastoma genesis.$328,996
R01 · FY2021 · CA · contact PI
Successive responses to oncogenic aberrations in retinoblastoma genesis.$395,084
R01 · FY2020 · CA · contact PI
Human Specific Signaling Circuitry in Cone Precursor Development$416,250
R01 · FY2019 · EY · contact PI
Successive responses to oncogenic aberrations in retinoblastoma genesis.$362,457
R01 · FY2019 · CA · contact PI
Human Specific Signaling Circuitry in Cone Precursor Development$416,250
R01 · FY2018 · EY · contact PI
Human Specific Signaling Circuitry in Cone Precursor Development$416,250
R01 · FY2017 · EY · contact PI
Human Specific Signaling Circuitry in Cone Precursor Development$416,250
R01 · FY2016 · EY · contact PI
Modeling Optic Nerve Hypoplasia with Patient iPSC-Derived Retinal Ganglion Cells$206,250
R21 · FY2016 · EY · contact PI
Cellular Predisposition to Retinoblastoma Tumorigenesis$336,150
R01 · FY2015 · CA · contact PI
Modeling Optic Nerve Hypoplasia with Patient iPSC-Derived Retinal Ganglion Cells$247,500
R21 · FY2015 · EY · contact PI
Cellular Predisposition to Retinoblastoma Tumorigenesis$302,392
R01 · FY2014 · CA · contact PI
Cellular Predisposition to Retinoblastoma Tumorigenesis$333,072
R01 · FY2013 · CA · contact PI
Cellular Predisposition to Retinoblastoma Tumorigenesis$23,674
R01 · FY2013 · CA · contact PI
Cellular Predisposition to Retinoblastoma Tumorigenesis$379,518
R01 · FY2012 · CA · contact PI
Cellular Predisposition to Retinoblastoma Tumorigenesis$370,007
R01 · FY2011 · CA · contact PI
FUNCTION OF PRB RELATED PROTEINS IN SKELETAL DEVELOPMENT$322,862
R01 · FY2001 · HD
FUNCTION OF PRB RELATED PROTEINS IN SKELETAL DEVELOPMENT$313,459
R01 · FY2000 · HD